<p>The phase II clinical study CAIN457A2223 (<a href="https://clinicaltrials.gov/ct2/show/NCT01537432">NCT01537432</a>) was designed to evaluate the proportion of patients achieving reversal of chronic plaque psoriasis at weeks 4 and 12 following multiple doses of secukinumab, administered subcutaneously, compared to placebo. 36 patients were enrolled in this study, with 24 being randomly assigned to the treatment arm and 12 to the placebo arm. Starting from week 13, all patients received multiple doses of secukinumab up to week 52 to study long term effects of secukinumab. The microarray gene expression data deposited in this dbGaP study are derived from the early (baseline to week 12) skin biopsies of this clinical trial.</p>

Microarray Gene Expression Data from Early Skin Biopsies of a Secukinumab    Clinical Trial in Psoriasis

1 selected publication including "IL-17A inhibition by secukinumab induces early clinical, histopatholog..." (161 citations)

Microarray Gene Expression Data from Early Skin Biopsies of a Secukinumab Clinical Trial in Psoriasis

IL-17A inhibition by secukinumab induces early clinical, histopathological, and molecular resolution of psoriasis.